Brilacidin for COVID-19: real-time analysis

Download Image

Post

c19early.org

Brilacidin for COVID-19

1 study with 120 patients

Serious outcome risk

Brilacidin

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Brilacidin studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)0%

Mortality (1)0%

RCTs (1)0%

Late (1)0%

00.511.5+

← Brilacidin
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Brilacidin is a small molecule host defense protein (HDP) mimetic with broad-spectrum antiviral and anti-inflammatory properties, potentially beneficial for COVID-19 by disrupting viral integrity and blocking viral entry via host cell heparan sulfate proteoglycans (HSPGs).


Jul 30 2021	Innovation Pharmaceuticals, NCT04784897	A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
Jul 30 2021	no change in mortality (p=1), 33% higher combined mortality/intubation (p=1), and 20% worse recovery (p=1). RCT 120 hospitalized COVID-19 patients showing no significant differences in pre-defined outcomes with brilacidin.